Log In
BCIQ
Print this Print this
 

ATI-50002 (formerly A-301)

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionJanus kinase-1 (JAK-1) and JAK-3 inhibitor
Molecular Target Janus kinase-1 (JAK-1) ; Janus kinase-3 (JAK-3)
Mechanism of ActionJanus kinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationAlopecia
Indication DetailsTreat patchy alopecia areata
Regulatory Designation
PartnerAclaris Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today